about
Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's diseaseNeuronal network disintegration: common pathways linking neurodegenerative diseasesPossible involvement of self-defense mechanisms in the preferential vulnerability of the striatum in Huntington's diseaseComprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocyclineNeuropeptide Y (NPY) in cerebrospinal fluid from patients with Huntington's Disease: increased NPY levels and differential degradation of the NPY1-30 fragment.Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participantsExtensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease miceAnalysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood.Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative DiseasesEating disturbance in behavioural-variant frontotemporal dementia.Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease.Eating and hypothalamus changes in behavioral-variant frontotemporal dementia.Oral and dental health in Huntington's disease - an observational studyVolumetric analysis of the hypothalamus in Huntington Disease using 3T MRI: the IMAGE-HD Study.Sleep Physiology Alterations Precede Plethoric Phenotypic Changes in R6/1 Huntington's Disease MiceA 24-Hour Study of the Hypothalamo-Pituitary Axes in Huntington's Disease.Environmental enrichment rescues female-specific hyperactivity of the hypothalamic-pituitary-adrenal axis in a model of Huntington's disease.Cross-phenotype association tests uncover genes mediating nutrient response in Drosophila.Euglycemic agent-mediated hypothalamic transcriptomic manipulation in the N171-82Q model of Huntington disease is related to their physiological efficacy.A Metabolic Study of Huntington's Disease.Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT.Impaired Nitric Oxide Mediated Vasodilation In The Peripheral Circulation In The R6/2 Mouse Model Of Huntington's DiseaseHypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications.Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse modelsNeocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouseMolecular mechanisms and potential therapeutical targets in Huntington's disease.Brain networks in Huntington disease.Energy deficit in Huntington disease: why it matters.Mitochondrial and metabolic-based protective strategies in Huntington's disease: the case of creatine and coenzyme Q.Progress in Huntington's disease: the search for markers of disease onset and progression.Regulation of L-type Ca2+ Channel Activity and Insulin Secretion by Huntingtin-associated Protein 1.Altered expression of 3-betahydroxysterol delta-24-reductase/selective Alzheimer's disease indicator-1 gene in Huntington's disease models.Corticosterone dysregulation exacerbates disease progression in the R6/2 transgenic mouse model of Huntington's disease.Mutant huntingtin fragment selectively suppresses Brn-2 POU domain transcription factor to mediate hypothalamic cell dysfunctionDifferential effects of early environmental enrichment on emotionality related behaviours in Huntington's disease transgenic mice.Growth hormone and ghrelin secretion are associated with clinical severity in Huntington's disease.Pregnancy and active Huntington disease: a rare combination.The relationship between cortisol and verbal memory in the early stages of Huntington's disease.Tolerability and efficacy of the monoaminergic stabilizer (-)-OSU6162 (PNU-96391A) in Huntington's disease: a double-blind cross-over study.
P2860
Q24647189-7D47ACCF-1EC8-4FDF-9200-3E51C0E22A91Q26750287-F2833D99-6267-4CFF-A0CE-70621A2A3E21Q27011417-47C45288-F2EE-468E-89E6-4006BEDE7AC3Q28748449-B749E191-6D42-4CF4-8308-5552171F1AC2Q30315395-66C79E6D-621A-443B-A8BC-079139EB2D7DQ30435217-9C150B96-5BB0-4FEA-B86C-28CC44382439Q30437914-796DA9D7-71C4-429D-85FE-53D6FF2A8674Q30480013-ABDC2B52-17A6-4531-B17C-A97730B64CFAQ33517121-D21EF448-0F9B-4FD1-8001-68D5B4AA78A0Q33624586-596B24F1-0202-430B-8870-D7BDF6751C24Q34185521-51612E76-55F7-4EDB-88D0-535E44F2C004Q34743269-4253EF13-61FD-472B-A03F-2B0D9AD93A0FQ34886007-11236757-D938-4AFC-846A-0BE4D508941CQ35020623-540ECA31-33D4-44CF-890F-B018027B83E7Q35058349-5A78F142-DDDF-48A5-85AF-1FE8A69C792AQ35597460-F6FD1DE2-732C-41B9-8B00-FEDC9669084FQ35797126-99E260BC-BCCC-4F96-A6AA-6F93BC0E3E05Q36136010-7D4D109E-AF1E-427A-89D7-BCC6704CF606Q36181271-1532930D-AEE1-445C-B05D-8D45D675573EQ36234711-9F54E680-F613-44FD-AD7A-4E0BA4157C6CQ36445216-32F2DAFC-08C6-4FED-8CD0-D4637D08CC56Q36763900-9D04927E-B271-4582-BA8B-CD0DFA43F340Q36903058-72A4D929-666C-4CEA-A52B-4C06C7253562Q37003956-08F03057-E154-418C-8F88-6EE346C0AEAFQ37112122-4FF8457D-494B-4329-A2AB-CB14160AEE32Q37294750-CFDF941D-EAD8-4019-8D7B-0CEB9E71D875Q37776087-50838F55-E095-448E-B97A-402341131292Q37834193-EE0E6229-E509-4356-B89C-4B63ABEB1E18Q37834195-A7A4EBD7-E2D4-4DC7-A36D-FCF632B36427Q37965763-E0C3AB73-4564-42A9-80C6-D8ABC1703DA2Q38385717-FE00B1A8-4DD5-4034-ABA0-1C4E1F2A44D5Q38746454-6CA7BC19-A92D-43E0-BF9D-859981BD9A87Q38986023-94C2AB05-507C-46FF-A870-D55269734ED0Q39629256-ADFFCD76-C18A-401C-9EE1-4113AE68561FQ40392188-8BAE9A3C-F9A5-464A-9B35-B7B1B7998E26Q42671677-E1684E8A-AEEF-4F5A-A3F1-D1A99B5820BFQ43257519-9AC977D1-08F3-4D52-BB6B-187FD8FADB27Q45288618-49526B44-ED3A-4055-ACA4-76BB8F6A341BQ45290829-41F3A2FA-176F-43FB-B443-C6198A2BA6BBQ45301837-F99A4D27-C9DB-4AC1-AB22-6D824556A073
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Hypothalamic-endocrine aspects in Huntington's disease.
@ast
Hypothalamic-endocrine aspects in Huntington's disease.
@en
type
label
Hypothalamic-endocrine aspects in Huntington's disease.
@ast
Hypothalamic-endocrine aspects in Huntington's disease.
@en
prefLabel
Hypothalamic-endocrine aspects in Huntington's disease.
@ast
Hypothalamic-endocrine aspects in Huntington's disease.
@en
P1476
Hypothalamic-endocrine aspects in Huntington's disease
@en
P2093
Asa Petersén
P2860
P304
P356
10.1111/J.1460-9568.2006.04985.X
P407
P50
P577
2006-08-21T00:00:00Z